CSBR · Champions Oncology, Inc.
Price & Indicators
Up next
Latest filings
Champions Oncology held its 2026 Annual Meeting on October 14, 2026, electing seven directors, approving executive compensation on an annual basis, and ratifying EisnerAmper LLP as auditor for fiscal year ending April 30, 2027.
Read the 8-KMetrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EPS - basic non-GAAP | $0.05 | first quarter of fiscal 2027 | — |
GAAP → non-GAAP reconciliationGAAP EPS – basic, GAAP -$0.03
+$0.06 Effect of stock-based compensation on EPS
+$0.02 Effect of depreciation and amortization on EPS
+$0 Effect of loss on equipment disposal on EPS
+$0 Effect of other expense (income), net on EPS
+$0 Effect of provision for tax on EPS
= Adjusted EPS - basic $0.05
|
|||
| Oncology services margin non-GAAP | 51% | first quarter of fiscal 2027 | — |
| Oncology services profit non-GAAP | 7.7M | first quarter of fiscal 2027 | — |
GAAP → non-GAAP reconciliationGAAP Loss from operations - GAAP -$409K
+$8.11M Research and Development, Sales and Marketing, General and Administrative, and Loss on disposal of equipment
= Oncology services profit $7.7M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CSBR
this stock
Champions Oncology, Inc.
|
$67.23M | -30.1% | +4.4% | — | 0.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.20B | +14.9% | +46.2% | 30.2 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.02B | +5.7% | +20.8% | 20.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.03B | +605.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 16, 2026
- This year
- 10
Champions Oncology held its 2026 Annual Meeting on October 14, 2026, electing seven directors, approving executive compensation on an annual basis, and ratifying EisnerAmper LLP as auditor for fiscal year ending April 30, 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CSBR | +0.4% | +0.8% | -19.2% | -3.4% | -30.1% |
| SPY | +0.1% | +0.7% | +4.9% | +0.9% | +12.9% |
| vs SPY | +0.3% | +0.1% | -24.1% | -4.3% | -43.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.